Site variability in treatment outcome in antidepressant trials

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 26, Issue 5, 2002, Pages 989-993

  Amsterdam, Jay D ^a   Brunswick, David J ^a  

^a The Science Center Philadelphia   (United States)

Author keywords

Antidepressants; Clinical trials; Fluoxetine; Study variables; Treatment outcome

Indexed keywords

ANTIDEPRESSANT AGENT; FLUOXETINE; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; KAPLAN MEIER METHOD; LONG TERM CARE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; RANDOMIZATION; RATING SCALE; RECURRENCE RISK; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; CHI-SQUARE DISTRIBUTION; CONTROLLED CLINICAL TRIALS; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FEMALE; FLUOXETINE; HUMANS; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0036592263     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-5846(02)00219-1     Document Type: Article

References (11)

1. Amsterdam J.D., Fawcett J., Quitkin F.M., Reimherr F.W., Rosenbaum J., Michelson D., Hornig-Rohan M., Beasley C. Fluoxetine and norfluoxetine plasma levels in major depression: a multi-center study. Am. J. Psychiatry. 154:1997;963-969.
2. Demitrack M.A., Faries D., Herrera J.M., DeBrota D.J., Potter W.Z. The problem of measurement error in multicenter clinical trials. Psychopharmacol. Bull. 34:1998;19-24.
3. Guy W. ECDEU Assessment for Psychopharmacology. revised ed. 1976;. Rockville, MD.
4. Hamilton M. A rating scale for depression. J. Neurol., Neurosurg. Psychiatry. 23:1960;56-62.
5. Hooper M., Brunswick D.J., Amsterdam J.D. Keep antidepressant drug trials. Presented at the 37th Annual Meeting ACNP, San Juan, Puerto Rico:1998.
6. Hooper, M.B., Brunswick, D.J., Amsterdam, J.D., Beasley, C., June 1999. Identifying sources of outcome variability in clinical drug trials. Presented at the NCDEU 39th Annual Meeting, Boca Raton.
7. Niklson I.A., Remitz P.-E., Sennef C. Factors that influence the outcome of placebo controlled antidepressant clinical trials. Psychopharmacol. Bull. 1997;41-51.
8. Reimherr F.W., Amsterdam J.D., Fawcett J., Quitkin F.M., Rosenbaum J., Beasley C., Michelson D., Roback P., Sundell K. Optimal length of continuation therapy: a prospective assessment during fluoxetine long-term treatment. Am. J. Psychiatry. 55:1998;1247-1253.
9. Small G.W., Schneider L.S., Hamilton S.H., Bystritsky A., Meyers B.S., Nemeroff C.B. Site variability in a multisite geriatric depression trial. Int. J. Geriatr. Psychiatry. 11:1996;1089-1095.
10. Spitzer R.L., Williams J.B.W., Gibbon M. Structured Clinical Interview for DSM-III-R (SCID). 1986;Biometrics Research, New York State Institute, New York.
11. Stahl S.M. Placebo controlled comparison of the selective serotonin reuptake inhibitors citalopram and sertraline. Biol. Psychiatry. 48:2000;894-901.